CLINICAL ROLE -
Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.
Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma
Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma
Venetoclax With 5-Azacytidine Effective in Treating Patients With Multiple Myeloma
Addressing the Challenges of Implementing Bispecific Antibodies in Health Care Centers
Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options